Benefits
Skin hydration and moisture retention
In laboratory (in-vitro) studies of the component botanicals, ginsenosides have been observed to support hyaluronic acid synthase activity in dermal fibroblasts, a proposed mechanism for skin moisture retention. This has not been demonstrated for oral Astrion in human trials.
Collagen synthesis and skin elasticity
In in-vitro fibroblast studies, Panax notoginseng and ginsenoside components have promoted type I procollagen synthesis, a proposed pathway for supporting the skin’s structural collagen matrix. Oral human efficacy for Astrion has not been established.
Skin antioxidant protection
The component botanicals show antioxidant activity in laboratory studies, including Nrf2-pathway activation in cell models — a proposed mechanism for protecting skin cells from oxidative stress. This has not been demonstrated for oral Astrion in humans.
Mechanism of action
Fibroblast TGF-β/Smad collagen induction and HA synthase activation
Proposed mechanism (based on in-vitro studies of the component botanicals, not oral human trials): the Astragalus/notoginseng saponins have been observed in cell studies to modulate TGF-β1 signaling in dermal fibroblasts and to upregulate hyaluronic acid synthase (HAS-2), pathways involved in skin collagen and hydration. Whether oral Astrion produces these dermal effects in humans has not been established.
Clinical trials
A non-PubMed-indexed study (Cosmetics, MDPI, 2025) of an Astragalus + Centella asiatica (ACS) blend — a different botanical combination than Astrion (Astragalus + Panax notoginseng).
Not applicable to Astrion — a study of a related but different blend.
This non-PubMed-indexed study reported skin improvements with an Astragalus + Centella (ACS) blend, but it is not a study of Astrion itself, and no oral human efficacy trial of Astrion has been published. Specific effect sizes are not independently verifiable.